Anabolic steroids are synthetic derivatives of testosterone . Nitrogen balance is improved with anabolic agents but only when there is sufficient intake of calories and protein . Whether this positive nitrogen balance is of primary benefit in the utilization of protein-building dietary substances has not been established. Oxymetholone enhances the production and urinary excretion of erythropoietin in patients with anemias due to bone marrow failure and often stimulates erythropoiesis in anemias due to deficient red cell production.
Dianabol is not an extremely androgenic steroid, its androgenicity has been structurally reduced, but androgenic side effects are still possible. Such side effects of Dianabol use include acne, accelerated hair loss in those predisposed to male pattern baldness and body hair growth. Most men should not have a problem with such effects, response will be the final dictator, but most will remain clear. Although the odds are in your favor, such effects are brought on by Methandrostenolone being metabolized by the 5-alpha reductase enzyme. This is the same enzyme responsible for the reduction of testosterone to dihydrotestosterone, but the overall conversion here will result in very low amounts of dihydromethandrostenolone. This tells us 5-alpha reductase inhibitors like Finasteride that are often used to combat androgenic side effects will have very little if any affect on Dianabol.
Despite its reduced androgenicity, Dianabol can promote virilization symptoms in women. Such symptoms include body hair growth, a deepening of the vocal chords and clitoral enlargement. It is possible for some women to use this steroid without virilization symptoms with extremely low doses, but the odds are not favorable. Most all women should choose anabolic steroids with less translating androgenic activity to meet their needs.
The effect of intensive lipid-lowering therapy on coronary atherosclerosis has been assessed by arteriography in hyperlipidemic patients. In these randomized, controlled clinical trials, patients were treated for two to four years by either conventional measures (diet, placebo, or in some cases low dose resin), or intensive combination therapy using diet plus colestipol (an anion exchange resin with a mechanism of action and an effect on serum lipids similar to that of QUESTRAN and QUESTRAN LIGHT) plus either nicotinic acid or lovastatin. When compared to conventional measures, intensive lipid-lowering combination therapy significantly reduced the frequency of progression and increased the frequency of regression of coronary atherosclerotic lesions in patients with or at risk for coronary artery disease.